AstraZeneca PLC (LSE:AZN) shared some disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy.
Phase III trials showed the drug did not achieve statistical significance for its primary endpoint of disease-free survival compared to placebo in early-stage non-small cell lung cancer.
In the trials, the drug was given to patients after complete tumour resection where their tumours expressed the ‘PD-L1’ checkpoint protein on 25% or more tumour cells.
“We are disappointed in the ADJUVANT BR.31 results,” said AstraZeneca’s executive vice president for oncology R&D, Susan Galbraith.
She added that elsewhere Imfinzi has proved successful in multiple other Phase III trials for patients with earlier stages of lung cancer.